» Articles » PMID: 33016801

Intravitreous Delivery of Melatonin Affects the Retinal Neuron Survival and Visual Signal Transmission: and Study

Overview
Journal Drug Deliv
Specialty Pharmacology
Date 2020 Oct 5
PMID 33016801
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Intravitreal delivery can maximize the intensity of therapeutic agents and extend their residence time within ocular tissue. Melatonin is a lipophilic molecule that crosses freely biological barriers and cell membranes. This study intends to investigate the effects of intravitreally delivered melatonin on mouse retina. The visual function of administered mice is assessed by electrophysiological and behavior examinations three weeks after intravitreal delivery. Moreover, multi-electrode array (MEA) was used to assess the electrical activities of retinal ganglion cells (RGCs). We found that intravitreal delivery of high dosage melatonin (400-500 µg/kg) destroyed the retinal architecture and impaired the visual function of mice. Conversely, the melatonin administration at low dose (100-300 µg/kg) did not have any significant effects on the photoreceptor survival or visual function. As shown in the MEA recording, the photoreceptors activity of the central region was more severely disturbed by the high dose melatonin. A pronounced augment of the spontaneous firing frequency was recorded in these mice received high dosage melatonin, indicating that intravitreal delivery of high dosage melatonin would affect the electrical activity of RGCs. Immunostaining assay showed that the vitality of cone photoreceptor was impaired by high dose melatonin. These findings suggest that intravitreal melatonin is not always beneficial for ocular tissues, especially when it is administered at high dosage. These data add new perspectives to current knowledge about melatonin delivery at the ocular level. Further therapeutic strategies should take into consideration of these risks that caused by delivery approach.

Citing Articles

The Role and Therapeutic Potential of Melatonin in Degenerative Fundus Diseases: Diabetes Retinopathy and Age-Related Macular Degeneration.

Ma C, Li H, Lu S, Li X Drug Des Devel Ther. 2024; 18:2329-2346.

PMID: 38911030 PMC: 11193467. DOI: 10.2147/DDDT.S471525.


Melatonin Maintains Inner Blood-Retinal Barrier by Regulating Microglia Inhibition of PI3K/Akt/Stat3/NF-κB Signaling Pathways in Experimental Diabetic Retinopathy.

Tang L, Zhang C, Lu L, Tian H, Liu K, Luo D Front Immunol. 2022; 13:831660.

PMID: 35371022 PMC: 8964465. DOI: 10.3389/fimmu.2022.831660.


Therapeutic Effects of Melatonin on Ocular Diseases: Knowledge Map and Perspective.

Yu H, Wang Q, Wu W, Zeng W, Feng Y Front Pharmacol. 2021; 12:721869.

PMID: 34795578 PMC: 8593251. DOI: 10.3389/fphar.2021.721869.

References
1.
Laurent V, Sengupta A, Sanchez-Bretano A, Hicks D, Tosini G . Melatonin signaling affects the timing in the daily rhythm of phagocytic activity by the retinal pigment epithelium. Exp Eye Res. 2017; 165:90-95. PMC: 6314190. DOI: 10.1016/j.exer.2017.09.007. View

2.
van Norren D, Vos J . Light damage to the retina: an historical approach. Eye (Lond). 2015; 30(2):169-72. PMC: 4763118. DOI: 10.1038/eye.2015.218. View

3.
Hamon A, Masson C, Bitard J, Gieser L, Roger J, Perron M . Retinal Degeneration Triggers the Activation of YAP/TEAD in Reactive Müller Cells. Invest Ophthalmol Vis Sci. 2017; 58(4):1941-1953. PMC: 6024660. DOI: 10.1167/iovs.16-21366. View

4.
Linsenmeier R, Zhang H . Retinal oxygen: from animals to humans. Prog Retin Eye Res. 2017; 58:115-151. PMC: 5441959. DOI: 10.1016/j.preteyeres.2017.01.003. View

5.
Eastlake K, Luis J, Limb G . Potential of Müller Glia for Retina Neuroprotection. Curr Eye Res. 2019; 45(3):339-348. DOI: 10.1080/02713683.2019.1648831. View